Latest / Making it in Manufacturing
This Model Could Replace Traditional CDMOs
What if you could access GMP manufacturing without giving up control, ownership, or flexibility? In this episode, a new model challenges how biotech companies think about scaling.
This week on Making It In Manufacturing, Harry Sloan sat down with Sarah Stevens, CEO of Chrysalis, with over 20 years of experience spanning CDMO services, technical operations, and leadership roles across biopharma manufacturing.
In this episode, Sarah Stevens covers:
(00:00) How Chrysalis is redefining the CDMO model with a hybrid approach that allows companies to retain control of IP, timelines, and…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.